Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Key Stats

• Today's Range: $6.92 to $7.57
• 50-Day Range: $6.05 to $8.69
• 52-Week Range: $2.12 to $12.55
• Volume: 37,408 shs
• Average Volume: 233,754 shs
• Market Capitalization: $13.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Neuphoria Therapeutics Stock Analysis - MarketRank™

Neuphoria Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 835th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Neuphoria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neuphoria Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Neuphoria Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.85) per share.

Price to Book Value per Share Ratio

Neuphoria Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NEUP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuphoria Therapeutics does not currently pay a dividend.

Dividend Growth

Neuphoria Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NEUP.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for NEUP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.69% of the stock of Neuphoria Therapeutics is held by insiders.

Percentage Held by Institutions

Only 15.90% of the stock of Neuphoria Therapeutics is held by institutions.

NEUP Stock Analysis - Frequently Asked Questions

How have NEUP shares performed this year?

Neuphoria Therapeutics' stock was trading at $3.20 at the beginning of the year. Since then, NEUP stock has increased by 119.4% and is now trading at $7.02.

How were Neuphoria Therapeutics' earnings last quarter?

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) posted its quarterly earnings data on Tuesday, May, 20th. The company reported $6.55 earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $7.02. The business had revenue of $15 million for the quarter.

Who are Neuphoria Therapeutics' major shareholders?

Top institutional investors of Neuphoria Therapeutics include AdvisorShares Investments LLC (3.60%).

How do I buy shares of Neuphoria Therapeutics?

Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/20/2025
• Today: 8/20/2025
• Next Earnings (Estimated): 9/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NEUP
• Previous Symbol: NASDAQ:NEUP
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: 61-8-8150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neuphoria Therapeutics: $21.00
• High Price Target: $21.00
• Low Price Target: $21.00
• Potential Upside/Downside: +174.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.01
• Quick Ratio: 11.01

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,436.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.85 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 1,880,000
• Free Float: 1,867,000
• Market Cap: $14.36 million
• Optionable: N/A
• Beta: 0.53